INT70134

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 1997
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 124
Total Number 125
Disease Relevance 81.96
Pain Relevance 9.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (TXK) nucleus (TXK) DNA binding (TXK)
cytoplasm (TXK)
Anatomy Link Frequency
fibroblasts 4
endothelial cells 3
corneal epithelial cell 3
platelet 2
T-cell 2
TXK (Homo sapiens)
Pain Link Frequency Relevance Heat
Kinase C 49 100.00 Very High Very High Very High
lidocaine 23 99.98 Very High Very High Very High
Inflammation 493 99.78 Very High Very High Very High
spinal dorsal horn 4 99.70 Very High Very High Very High
tetrodotoxin 24 99.66 Very High Very High Very High
antagonist 83 99.56 Very High Very High Very High
Inflammatory mediators 12 99.56 Very High Very High Very High
vincristine 9 99.48 Very High Very High Very High
Bioavailability 39 99.36 Very High Very High Very High
Potency 65 99.20 Very High Very High Very High
Disease Link Frequency Relevance Heat
Apoptosis 616 99.88 Very High Very High Very High
Solid Tumor 166 99.88 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 862 99.80 Very High Very High Very High
INFLAMMATION 547 99.78 Very High Very High Very High
Prostate Cancer 107 99.78 Very High Very High Very High
Disease Progression 150 99.68 Very High Very High Very High
Cancer 3449 99.60 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 12 99.42 Very High Very High Very High
Cardiovascular Disorder Under Development 58 99.36 Very High Very High Very High
Neointima 1 99.36 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Both responses could be abrogated by ARg-Gly-Asp (RGD)-containing peptides, inhibition of tyrosine kinase activity, and disruption of the cytoskeleton.
Negative_regulation (inhibition) of tyrosine kinase
1) Confidence 0.23 Published 1997 Journal J. Bone Miner. Res. Section Abstract Doc Link 9200014 Disease Relevance 0.09 Pain Relevance 0.17
Tyrosine kinase inhibition with tyrphostin A23 partially blocked the increase induced by oxytocin but had no effect on LPA-induced stress fiber formation.
Negative_regulation (inhibition) of Tyrosine kinase associated with stress
2) Confidence 0.20 Published 2001 Journal Biol. Reprod. Section Abstract Doc Link 11466206 Disease Relevance 0.74 Pain Relevance 0.16
The authors hypothesized that lidocaine would suppress tyrosine kinase activity of EGFR and would impair corneal epithelial cell proliferation.
Negative_regulation (suppress) of tyrosine kinase in corneal epithelial cell associated with lidocaine
3) Confidence 0.15 Published 2004 Journal Anesthesiology Section Abstract Doc Link 15114219 Disease Relevance 0.07 Pain Relevance 0.47
CONCLUSION: Lidocaine directly inhibits tyrosine kinase activity of EGFR and suppresses the corneal epithelial cell proliferation.


Negative_regulation (inhibits) of tyrosine kinase in corneal epithelial cell
4) Confidence 0.15 Published 2004 Journal Anesthesiology Section Body Doc Link 15114219 Disease Relevance 0 Pain Relevance 0
There are various reasons for the ineffectiveness of imatinib monotherapy in ovarian cancer: downregulation of c-kit and PDGFR may lead to induction of VEGF, inhibition of a single tyrosine kinase might be insufficient to impact downstream signaling cascades, and the molecular targets of imatinib might not be relevant in the occurrence of ovarian cancer in comparison with gastrointestinal stromal tumor or chronic myeloid leukemia where a single specific mutation or a translocation, respectively, can be responsible for the genesis of these two cancers [62].
Negative_regulation (inhibition) of tyrosine kinase associated with leukemia, cancer, ovarian cancer and gastrointestinal stromal tumor
5) Confidence 0.15 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 1.08 Pain Relevance 0
VEGF signaling pathways have been targeted for treatment by the use of anti-VEGF monoclonal antibodies, antibodies binding to VEGFR and VEGFR tyrosine kinase inhibitors.
Negative_regulation (inhibitors) of tyrosine kinase
6) Confidence 0.14 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.63 Pain Relevance 0.03
Vatalanib is a pan-VEGFR tyrosine kinase inhibitor with activity against VEGFR-1, VEGFR-2 and VEGFR-3.
Negative_regulation (inhibitor) of tyrosine kinase
7) Confidence 0.14 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.63 Pain Relevance 0.03
Lidocaine inhibits tyrosine kinase activity of the epidermal growth factor receptor and suppresses proliferation of corneal epithelial cells.
Negative_regulation (inhibits) of tyrosine kinase in corneal epithelial cells associated with lidocaine
8) Confidence 0.13 Published 2004 Journal Anesthesiology Section Title Doc Link 15114219 Disease Relevance 0.09 Pain Relevance 0.52
The authors' previous study revealed that lidocaine inhibits the activity of tyrosine kinase receptors through the interaction with specific amino acid sequences around autophosphorylation sites, including acidic, basic, and aromatic amino acids.
Negative_regulation (inhibits) of tyrosine kinase associated with lidocaine
9) Confidence 0.11 Published 2004 Journal Anesthesiology Section Abstract Doc Link 15114219 Disease Relevance 0.09 Pain Relevance 0.51
VEGFR Tyrosine Kinase Inhibitors

Cediranib (AZD2171, CED) is a highly selective and potent oral tyrosine kinase inhibitor (TKI) of VEGFR1, VEGFR2, VEGFR3, and c-Kit.

Negative_regulation (inhibitor) of tyrosine kinase associated with camurati-engelmann disease
10) Confidence 0.11 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 2.10 Pain Relevance 0.32
Semaxinib (SU5416) is a tyrosine kinase inhibitor with activity against VEGFR2.
Negative_regulation (inhibitor) of tyrosine kinase
11) Confidence 0.11 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 1.54 Pain Relevance 0.23
Tyrosine kinase inhibitors of VEGF
Negative_regulation (inhibitors) of Tyrosine kinase
12) Confidence 0.11 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 1.76 Pain Relevance 0.24
Both the selective CB1 and TRPV1 agonists (i.e., WIN55,212-2 [WIN] and capsaicin [CAP], respectively) induced EGFR phosphorylation whereas either inhibition of its tyrosine kinase activity with AG1478 or functional blockage eliminated this response.
Negative_regulation (inhibition) of tyrosine kinase associated with qutenza, cannabinoid receptor and agonist
13) Confidence 0.11 Published 2010 Journal Exp. Eye Res. Section Abstract Doc Link 20619260 Disease Relevance 0.17 Pain Relevance 0.57
Currently erlotinib is the sole tyrosine kinase inhibitor approved for use in pancreatic cancer.
Negative_regulation (inhibitor) of tyrosine kinase associated with pancreatic cancer
14) Confidence 0.10 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.57 Pain Relevance 0
Tyrosine kinase inhibitors, such as emodin, which block HER-2 phosphorylation
Negative_regulation (inhibitors) of Tyrosine kinase
15) Confidence 0.10 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.75 Pain Relevance 0
Despite the single case series report regarding Cetuximab, we identified three case reports documenting sparing of the skin in the previous radiation field in patients treated with erlotinib, a small molecule inhibitor of tyrosine kinase.
Negative_regulation (inhibitor) of tyrosine kinase in skin
16) Confidence 0.10 Published 2010 Journal Radiat Oncol Section Body Doc Link PMC2893190 Disease Relevance 0.74 Pain Relevance 0.05
Since EGFR inhibitors alone have shown limited activity in epithelial ovarian cancer [28, 29], it was postulated that combining an EGFR tyrosine kinase inhibitor like erlotinib with BEV might improve response rates.
Negative_regulation (inhibitor) of tyrosine kinase associated with ovarian cancer
17) Confidence 0.10 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 0.32 Pain Relevance 0
PF-00299804 is an orally active pan-HER tyrosine kinase inhibitor which specifically and irreversibly binds to and inhibits HER1, HER2 and HER4 which was evaluated in non-small cell lung cancer patients at ASCO 2008 but also exhibits potential activity in HER2 positive breast cancer patients.[67]
Negative_regulation (inhibitor) of tyrosine kinase in lung associated with lung cancer and breast cancer
18) Confidence 0.09 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 1.05 Pain Relevance 0.06
Motesanib is a small molecule tyrosine kinase inhibitor of VEGF that targets VEGFR 1, 2, 3 and PDGF that has been evaluated in preclinical models in combination with either tamoxifen or docetaxel and was shown to have potential use in breast cancer.[68] A large phase II clinical trial is ongoing evaluating motesanib and paclitaxel in the treatment of breast cancer).[47]
Negative_regulation (inhibitor) of molecule tyrosine kinase associated with breast cancer
19) Confidence 0.09 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 0.99 Pain Relevance 0.05
Gefitinib and erlotinib both specifically inhibit the EGFR tyrosine kinase and have demonstrated inhibitory activity in models of hormone-resistant breast cancer [37, 38].
Negative_regulation (inhibit) of tyrosine kinase associated with breast cancer
20) Confidence 0.09 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001220 Disease Relevance 0.33 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox